Proteolysis targeting chimeras (PROTACs) offer a fast and reversible chemical knock-down approach to control protein function. The impact of PROTAC platform has changed the landscape of drug discovery and development.

Medicilon’s PROTAC drug discovery technology platform covers the currently popular target protein ligands. We have established a linker system with an extensive collection of bifunctional linkers. Together with our expanding E3 ubiquitin ligase binder library, we can efficiently synthesize a substantial amount of highly active PROTAC bispecific small molecules, which would have the potential to significantly facilitate ithe drug discovery and development process. In addition, Medicilon has established as well as improved the PROTAC biological screening and testing platform throughout the pre-clinical stages.

Medicilon’s strong technical expertise and flexible service models allow individualized and customized projects ranging from sole chemical synthesis to in vitro and/or in vivo service, and to more comprehensive integrated package support. Our laboratories are US FDA and China NMPA accredited, and we will soon receive the European OECD GLP accreditation as well. We have successfully filled over 150 IND submissions worldwide. Medicilon is confident in providing efficient, cost-effective, and professional services to support our clients in reaching their drug development milestones.

Read More...

Download PDF